描述
Recombinant Human CD70/TNFSF7/CD27 Ligand Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gln39-Pro193) of human CD70/TNFSF7/CD27 Ligand (Accession #NP_001243.1) fused with and a 6×His tag at the N-terminus.
生物活性
Measured by its binding ability in a functional ELISA.Immobilized Human TNFSF7 (Catalog: RP01720) at 2 μg/mL (100 μL/well) can bind Human TNFRSF7 (Catalog: RP01358) with a linear range of 0.2-82 ng/mL.
制剂
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
储存
Store the lyophilized protein at -20°C to -80°C for 12 months.
After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；
复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。
复溶
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid votex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。
背景信息
CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.
别名
CD27L; LPFS3; CD27-L; CD27LG; TNFSF7; TNLG8A;CD70
